Molecular Partners AG: Half-year results 2015 of Molecular Partners AG Montag, 24. August 2015 - 13:14

Molecular Partners AG: Half-year results 2015 of Molecular Partners AG

Wednesday, 02 September 2015, 2:00pm (CET) – Conference call & audio webcast for media, analysts and investors

Molecular Partners AG cordially invites you to participate in the conference call or audio webcast of the company’s Half-year results 2015 which will take place as follows:

Date:	Wednesday, 02 September 2015
Time:	2:00pm CET (1:00pm GMT, 8:00am EST)

The Half-year 2015 Report and additional information is available on
investors.molecularpartners.com/investor-documents/annual-reports from 7:00am (CET) on on Wednesday, 02 September 2015.

Best regards,
Thomas Schneckenburger
Investor Relations Molecular Partners AG

Dial-ins for the conference call:
Switzerland / Europe	+41 (0) 58 310 5000
UK	+44 (0) 203 059 5862
USA	+1 (1) 631 570 5613

Please dial-in approximately 10 minutes before the start of the presentation in order to register. Participants will have the opportunity to ask questions after the presentation.

To follow the audio webcast of the presentation:
The audio webcast will be accessible, both live and as a replay, on www.molecularpartners.com, along with the accompanying presentation slides.

Please note that there will be no facility to ask questions via the webcast.
You will need to log in and register prior to the event.

Investor distribution list:
If you wish to be removed from the distribution list, please email us atinvestors@molecularpartners.com.

About Molecular Partners AG

Molecular Partners is a public, clinical‐stage, biopharmaceutical company listed on the SIX Swiss Exchange (ticker symbol: MOLN) that is developing a new powerful class of therapies known as DARPins. DARPins are potent, specific and versatile small protein therapies which have the potential to offer benefits over conventional monoclonal antibodies or other currently available protein therapeutics. The DARPin technology has the potential to enable a multi-specific approach to treatment which enables DARPins to target multiple pathways, or multiple epitopes on a single target to achieve substantial patient benefit. DARPins have the potential to advance modern medicine and significantly improve the treatment of serious diseases, including cancer and sight‐threatening disorders.

Molecular Partners has four compounds in various stages of clinical and preclinical development and several more in the research stage, with a current focus on ophthalmology and oncology. Its most advanced product candidate is abicipar. The company has ongoing research and development partnerships with leading pharmaceutical companies including Allergan and Janssen and is backed by established biotech investors.

For more information regarding Molecular Partners go to: www.molecularpartners.com.